<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00202618</url>
  </required_header>
  <id_info>
    <org_study_id>SMART001</org_study_id>
    <nct_id>NCT00202618</nct_id>
  </id_info>
  <brief_title>Rationale and Design for Shiga Microalbuminuria Reduction Trial</brief_title>
  <official_title>The Reduction of Microalbuminuria in Japanese Hypertensive Subjects With Type 2 Diabetes Mellitus Treated With Valsartan or Amlodipine: Study Design for the Shiga Microalbuminuria Reduction Trial (SMART)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiga University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiga University</source>
  <brief_summary>
    <textblock>
      The purpose of this trial are to evaluate the reduction of urinary albumin excretion by an
      angiotensin receptor blocker (ARB), valsartan, in comparison with a calcium channel blocker
      (CCB), amlodipine, in Japanese hypertensive patients with type 2 diabetes mellitus and
      microalbuminuria under strict blood pressure control, and to compare the additional effects
      of an ARB or a CCB in combination with angiotensin-converting enzyme (ACE) inhibitor
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Microalbuminuria in diabetic patients is an established risk marker for the progression of
      diabetic nephropathy and for cardiovascular mortality. Intervention trials have demonstrated
      that drugs that blockade the renin-angiotensin system can reduce microalbuminuria in
      Caucasian patients with type 2 diabetes mellitus and microalbuminuria, regardless of blood
      pressure level. However, it remains uncertain whether angiotensin receptor blockers or
      calcium channel blockers give a greater reduction of microalbuminuria. The Shiga
      Microalbuminuria Reduction Trial (SMART) is a prospective, multicentre, randomized,
      active-controlled, two-arm parallel treatment group comparison study aimed at evaluating
      reduction of microalbuminuria in 160 Japanese hypertensive patients with type 2 diabetes
      mellitus and microalbuminuria. The trial consists of an 8-week observation period for
      screening and washout, and a 24-week intervention period. After the observation period,
      patients are randomized to either amlodipine 5 mg once daily or valsartan 80 mg once daily as
      an initial dose. After four weeks, if patients cannot achieve the target blood pressure
      (&lt;130/80 mmHg) with the initial dose of a study drug, doses are titrated up to amlodipine 10
      mg once daily or valsartan 160 mg once daily. The primary endpoints are a change in the rate
      of urinary albumin excretion from baseline, a normalization of microalbuminuria, and a 50%
      reduction in urinary albumin excretion from baseline, which are compared between treatment
      groups. This study will provide additional data for the treatment of hypertension and
      microalbuminuria and has important health care implications for Japanese patients with type 2
      diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2003</start_date>
  <completion_date>June 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A change in the rate of urinary albumin excretion (UAE) from the baseline to the end of study</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>A normalization of microalbuminuria (normoalbuminuria)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>A 50% reduction in UAE from the baseline</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>A change in urinary type IV collagen from the baseline to the end of the intervention period</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A change in high sensitivity C-reactive protein (hsCRP) from the baseline to the end of the intervention period</measure>
  </secondary_outcome>
  <enrollment>160</enrollment>
  <condition>Hypertension</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Albuminuria</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hypertensive patient with type 2 diabetes

          -  Microalbuminuria defined as a urinary albumin excretion of 30 to 300 mg/gCr

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  Pregnant women and women of childbearing potential

          -  Severe hypertension (&gt; 180/110 mmHg), malignant hypertension, secondary hypertension

          -  History of cardiovascular diseases in the preceding 6 months (including symptomatic
             heart failure, unstable angina, myocardial infarction, the performance of percutaneous
             transluminal coronary angioplasty [PTCA], or coronary artery bypass graft [CABG],
             severe arrhythmia, or second or third degree atrioventricular [AV] block)

          -  History of clinically significant valvular disease (e.g., aortic stenosis, mitral
             insufficiency)

          -  History of cerebral infarction, cerebral hemorrhage, or transient ischemic attack

          -  Serum creatinine level &gt;1.5 mg/dl

          -  Persistent hematuria

          -  Serum potassium &gt; 5.6 mEq/L (hyperkalemia)

          -  Severe hepatic disorder (e.g., hepatic failure, hepatic cirrhosis)

          -  Complication of an allergy of potential clinical concern

          -  Hypersensitivity to ARBs or CCBs

          -  Gastrointestinal surgery or gastrointestinal disorders which could interfere with drug
             absorption

          -  Autoimmune disease

          -  Participation in any intervention trial within 3 months prior to the observation
             period

          -  Patients who are unwilling or unable to comply with the trial protocol

          -  Concomitant use of other ARBs, CCBs, or potassium-retaining diuretics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Atsunori Kashiwagi, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Shiga University of Medical Science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Atsunori Kashiwagi, Professor</last_name>
    <phone>81-77-548-2221</phone>
    <email>kasiwagi@belle.shiga-med.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hiroshi Maegawa, A. Professor</last_name>
    <phone>81-77-548-2222</phone>
    <email>maegawa@belle.shiga-med.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shiga University of Medical Science</name>
      <address>
        <city>Otsu</city>
        <state>Shiga</state>
        <zip>520-2192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atsunori Kashiwagi, Professor</last_name>
      <phone>81-77-548-2221</phone>
      <email>kasiwagi@belle.shiga-med.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Hiroshi Maegawa, A. Professor</last_name>
      <phone>81-77-548-2222</phone>
      <email>maegawa@belle.shiga-med.ac.jp</email>
    </contact_backup>
    <investigator>
      <last_name>Hiroshi Maegawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yasuo Kida</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shu Yamada</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Masataka Nishimura</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tetsuro Arimura</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Noriko Takahara</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katsuya Egawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Masanori Iwanishi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Toshiki Fujita</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aya Kadota</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>April 27, 2006</last_update_submitted>
  <last_update_submitted_qc>April 27, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2006</last_update_posted>
  <keyword>Hypertension</keyword>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Microalbuminuria</keyword>
  <keyword>Amlodipine</keyword>
  <keyword>Calcium channel blocker</keyword>
  <keyword>Valsartan</keyword>
  <keyword>Angiotensin type 2 receptor blocker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Albuminuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 23, 2011</submitted>
    <returned>November 29, 2011</returned>
    <submitted>January 10, 2012</submitted>
    <returned>February 9, 2012</returned>
    <submitted>March 15, 2012</submitted>
    <returned>April 9, 2012</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

